治愈性抗凝可预防COVID-19患者内皮损伤
研究分析96例连续疑似COVID-19住院患者的临床和生物学特征,包括止血检测和循环内皮细胞(CEC)定量。66例SARS-CoV-2阳性患者D-二聚体>500 ng/mL比例更高(74.2% vs 43.3%,P=0.007),入院时CEC更多(P=0.008);入院前接受治愈性抗凝的阳性患者CEC更少(P=0.02),同时使用ACEI/ARB者更少(P=0.007)。结论认为治愈性抗凝可能预防COVID-19相关凝血病和内皮损伤。
要点
- COVID-19阳性患者D-二聚体>500 ng/mL比例高于阴性患者(74.2% vs 43.3%,P=0.007)。
- COVID-19阳性患者入院时循环内皮细胞显著多于阴性患者(P=0.008)。
- 入院前治愈性抗凝的COVID-19阳性患者循环内皮细胞更少(P=0.02)。
核心结论
- 治愈性抗凝可能预防COVID-19相关凝血病和内皮损伤。
研究设计与样本
- 研究分析了96例连续疑似COVID-19感染并符合住院标准的患者入院时的临床和生物学特征,包括止血检测和循环内皮细胞(CEC)定量。
- 66例患者SARS-CoV-2检测阳性。
主要发现
- COVID-19阳性患者入院时更常出现发热(P=0.02)、咳嗽(P=0.03)和CT扫描肺炎(P=0.002)。
- D-二聚体>500 ng/mL的患病率在COVID-19阳性患者中更高(74.2% vs 43.3%,P=0.007)。
- 未发现弥散性血管内凝血征象。
- 在受试者工作特征曲线分析中,将D-二聚体>500 ng/mL加入性别和CT扫描肺炎显著增加了COVID-19诊断的曲线下面积。
- COVID-19阳性患者入院时CEC显著多于COVID-19阴性患者(P=0.008)。
关键数值与推荐
- D-二聚体>500 ng/mL的患病率:COVID-19阳性患者74.2% vs COVID-19阴性患者43.3%(P=0.007)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease-2019 (COVID-19) has been associated with cardiovascular complications and coagulation disorders. OBJECTIVES: To explore the coagulopathy and endothelial dysfunction in COVID-19 patients. METHODS: The study analyzed clinical and biological profiles of patients with suspected COVID-19 infection at admission, including hemostasis tests and quantification of circulating endothelial cells (CECs). RESULTS: Among 96 consecutive COVID-19-suspected patients fulfilling criteria for hospitalization, 66 were tested positive for SARS-CoV-2. COVID-19-positive patients were more likely to present with fever (P = .02), cough (P = .03), and pneumonia at computed tomography (CT) scan (P = .002) at admission. Prevalence of D-dimer >500 ng/mL was higher in COVID-19-positive patients (74.2% versus 43.3%; P = .007). No sign of disseminated intravascular coagulation were identified. Adding D-dimers >500 ng/mL to gender and pneumonia at CT scan in receiver operating characteristic curve analysis significantly increased area under the curve for COVID-19 diagnosis. COVID-19-positive patients had significantly more CECs at admission (P = .008) than COVID-19-negative ones. COVID-19-positive patients treated with curative anticoagulant prior to admission had fewer CECs (P = .02) than those without. Interestingly, patients treated with curative anticoagulation and angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers had even fewer CECs (P = .007). CONCLUSION: Curative anticoagulation could prevent COVID-19-associated coagulopathy and endothelial lesion.
引用
- Khider L, Gendron N, Goudot G, et al. Curative anticoagulation prevents endothelial lesion in COVID-19 patients. J Thromb Haemost. 2020. PMID: 32558198. doi:10.1111/jth.14968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。